Loading…
The Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh, called for greater private sector participation in India's biotechnology ecosystem at a meeting with senior officials of the Biotechnology Industry Research Assistance Council (BIRAC) in New Delhi.
The BIRAC Research, Development and Innovation Fund (BIRAC-RDIF) is a component of the Government's Rs 1 lakh crore RDI Fund, launched by the Prime Minister on 3 November 2025, managed by the Anusandhan National Research Foundation and the Department of Science and Technology, with BIRAC as Second Level Fund Manager for biotechnology.
BIRAC-RDIF supports high-risk, technology-intensive projects across Technology Readiness Levels 4 to 9, with assistance of Rs 5 crore to Rs 200 crore covering up to 50% of project cost, through collateral-free long-term loans, equity and hybrid instruments.
The first National Call for Proposals was launched on 13 February 2026; 198 applications have been received, screening of the first 50 is complete and eight Eligible Technology Entities have been selected on the Investment Committee's recommendation and are undergoing due diligence.
India hosts more than 1,700 Global Capability Centres employing around 1.9 million professionals; BIRAC will map life sciences GCC requirements and connect them with BioE3 bio-foundries, bio-incubators and startups, and has proposed a BIRAC Startup Investor Connect platform.
Technology Readiness Level is a nine-point scale describing how far a technology has travelled from idea to market. TRL 1 to 3 covers basic principles, concept formulation and early proof of concept — laboratory work that research grants have always funded. TRL 9 is a proven system operating in its final form in a real environment. The gap in between, roughly TRL 4 to 7 where a validated laboratory result must become a working prototype and then a manufacturable product, is the stage venture capital finds too risky and research grants do not cover. It is known in innovation policy as the 'valley of death', and Indian biotechnology has lost a great many promising results in it. BIRAC-RDIF is deliberately aimed at exactly this band. That is also why its instruments are unusual for a government science programme: collateral-free long-term loans, equity and hybrid instruments rather than grants. A grant funds research; a loan or equity stake funds a business, and requires the recipient to build one. The 50% cap on project cost forces the promoter or a co-investor to bring the other half, which is the mechanism by which public money is meant to pull private money in rather than substitute for it.
Simple Analogy: Research grants build the bridge from the bank to the middle of the river. Venture capital builds it from the far bank inward. RDIF funds the span in the middle that neither will pay for.
Nurtures and promotes the biotechnology industry, de-risks early innovation and bridges academia and industry; designated Second Level Fund Manager for biotechnology under the RDI Fund
The apex body for funding and directing research in India; manages the RDI Fund along with the Department of Science and Technology
The department under the Ministry of Science and Technology responsible for biotechnology policy, research funding and institutions, and BIRAC's parent
Co-manages the RDI Fund with ANRF and houses the RDI cell
Comprises external experts and recommends Eligible Technology Entities for support after screening and evaluation; a dedicated BIRAC-RDIF division has been set up to ring-fence implementation of the Fund
Enhance private sector participation in R&D and finance high-risk, high-impact innovation including deep-tech startups
Key: A Rs 1 lakh crore fund launched by the Prime Minister on 3 November 2025, managed by ANRF and DST, providing long-term financing or refinancing at low or nil interest rates through Second Level Fund Managers such as BIRAC
Support development and commercialisation of indigenous biotechnology innovations
Key: Rs 5 crore to Rs 200 crore per entity covering up to 50% of project cost across TRL 4 to 9, through collateral-free long-term loans, equity and hybrid instruments with a strategic co-investment framework; implemented through a ring-fenced BIRAC-RDIF division
Biotechnology for Economy, Environment and Employment — foster high-performance biomanufacturing
Key: Approved by the Union Cabinet on 24 August 2024; establishes Biomanufacturing and Bio-AI hubs and bio-foundries, with the stated ambition of making India a global hub for high-performance biomanufacturing by 2047. BIRAC is to connect Global Capability Centres with BioE3 bio-foundries, bio-incubators and startups
Bring investment-ready biotechnology startups together with investors
Key: A proposed dedicated platform to build awareness of biotechnology opportunities, facilitate strategic partnerships, strengthen investment networks and accelerate commercialisation — aimed at the growth-stage capital gap
Direct corporate social responsibility spending towards biotechnology-led social innovation
Key: BIRAC proposes to use its scientific due-diligence capability, nationwide network and grant-management framework as a CSR implementing agency, in areas including affordable healthcare, diagnostics, maternal and child health, nutrition, climate-resilient agriculture and skill development
GCCs — offshore centres that multinational firms run as in-house capability hubs rather than outsourced vendors — have moved up the value chain into R&D; with more than 1,700 in India employing about 1.9 million people, life sciences GCCs are being courted as a source of both demand and research capacity for the domestic biotech ecosystem
The Anusandhan National Research Foundation Act, 2023 repealed the Science and Engineering Research Board Act, 2008 and dissolved SERB, consolidating research funding under one apex body — a structural reform that the RDI Fund's architecture now sits on
Section 135 of the Companies Act mandates CSR spending by qualifying companies, and healthcare is among the largest recipient sectors — which is what makes BIRAC's proposal to act as a CSR implementing agency financially significant
The BioE3 Policy's target of making India a global biomanufacturing hub by 2047 ties this funding architecture to the wider Viksit Bharat 2047 framing that runs through the release
GS Paper 3 > Science and Technology > Biotechnology; Indian Economy > Investment Models and Innovation
General Awareness > Government Funds and Schemes
General Awareness > Science and Government Bodies
With reference to "Blockchain Technology", consider the following statements: 1. It is a public ledger that everyone can inspect, but which no single user controls. 2. The structure and design of blockchain is such that all the data in it are about cryptocurrency only. 3. Applications that depend on basic features of blockchain can be developed without anybody's permission. Which of the statements given above is/are correct?
Answer: 1 and 3 only
Research funding institutions, the BioE3 Policy and ANRF are current and recurring Prelims science-and-technology material
Biotechnology Industry Research Assistance Council — a Section 8 company set up by the Department of Biotechnology in 2012 to promote the biotechnology industry
The Rs 1 lakh crore Research, Development and Innovation Fund launched on 3 November 2025, managed by ANRF and DST, for deep-tech and high-impact indigenous innovation
A nine-point scale measuring a technology's maturity from basic principles (TRL 1) to a proven system in operation (TRL 9); BIRAC-RDIF covers TRL 4 to 9
Biotechnology for Economy, Environment and Employment — approved by the Union Cabinet on 24 August 2024 to foster high-performance biomanufacturing through Biomanufacturing and Bio-AI hubs and bio-foundries
An offshore centre run in-house by a multinational as a capability hub rather than an outsourced vendor; India hosts more than 1,700 employing around 1.9 million professionals